

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

86957254 W

July 26, 2007

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

PATEL ET AL.

APPLICATION NO: 10/743,367 FILED: DECEMBER 22, 2003

FOR: EXTENDED RELEASE ANTIBIOTIC COMPOSITION

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 3, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

07/27/2007 RMEBRAHT 00000043 190134 10743367

02 FC:1806


180.00 DA

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (609) 627-8508

Date: 02/54

Respectfully submitted,

Joseph T. Majka / Attorney for Applicants Reg. No. 30,570



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

PATEL ET AL.

APPLICATION NO: 10/743,367 FILED: DECEMBER 22, 2003

FOR: EXTENDED RELEASE ANTIBIOTIC COMPOSITION

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(609) 627-8508

Date: 07/26/07

Joseph T. Majka

Attorney for Applicants

Reg. No. 30,570

FORM PTO-1449 (REV. 7-85)

AT

EXAMINER

1986, pages 181-183

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ©33515P1 APPLICATION NO. 10/743,367 **APPLICANT** PATEL ET AL. **FILING DATE DECEMBER 22, 2003**

Group 1615

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						
			FOREIGN F	ATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	AM						
	AN						
-	AO						
	AP						
	AQ						
		OTHER DOC	UMENTS (Incl	uding Author, Title, Date, P	ertinent pages, E	tc.)	
	AR	Dow Excipients, METI	HOCEL Product	s, www.dow.com			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Methlycellulose, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association,

DATE CONSIDERED